DOUBLE BOND PHARMACEUTICAL INTERNATIONAL AB CLASS B
NNGM:DBP.B0.11
SEK
+0.00
(+0.91%)
DOUBLE BOND PHARMACEUTICAL INTERNATIONAL AB CLASS B
NGM:DBP.B
(Nordic Growth Market)
Recent
price
0.11
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Double Bond Pharmaceutical International AB is a clinical-stage biopharmaceutical company that develops targeted therapies for oncology, infectious diseases, and autoimmune conditions utilizing proprietary organ-specific drug delivery systems. Founded in 2014 and headquartered in Uppsala, Sweden, the company specializes in reformulating established active pharmaceutical ingredients into site-directed therapeutics to improve treatment efficacy, enhance local biodistribution, and mitigate systemic toxicity. The company conducts operations across the Nordic region and broader European markets, targeting hospitals, specialized oncology centers, healthcare systems, and medical distribution channels through its drug development and commercial distribution arms. The company's core product candidates, technologies, and services include: BeloGal, a proprietary organ-specific drug delivery platform engineered to guide therapeutic compounds directly to targeted organs and tissues; SI-053 (Temodex), an intracavitary, locally acting hydrogel formulation of temozolomide administered directly into the surgical resection cavity for the treatment of glioblastoma multiforme, which holds Orphan Drug Designation from the European Medicines Agency (EMA); SA-033, a liver-targeted doxorubicin formulation utilizing the BeloGal system for the treatment of hepatoblastoma, also designated as an orphan medicinal product by the EMA; Belopenem, an organ-directed formulation of meropenem developed for the targeted treatment of severe pneumonia and bacterial lung infections; and commercial pharmaceutical and healthcare distribution operations managed via its wholly owned subsidiary Drugsson AB, which distributes in-licensed prescription pharmaceuticals, over-the-counter products, and medical devices in Nordic and European markets. In recent developments, Double Bond Pharmaceutical International AB has advanced regulatory, manufacturing, and clinical execution for its lead neuro-oncology program SI-053. The company optimized and validated EU-cGMP compliant manufacturing processes for SI-053 and re-engaged global clinical research organization Allucent to support Phase 1 clinical trial initiation. To reinforce its clinical profile with real-world clinical data, the company entered into strategic research collaborations with the N.N. Alexandrov National Cancer Centre and Karolinska Institutet to conduct comprehensive Real-World Evidence (RWE) studies benchmarked against modern World Health Organization molecular classification standards. This research confirmed a 5.6-month survival advantage in glioblastoma patients treated with Temodex, leading to the selection and presentation of the clinical findings at the Annual Meeting of the Society for Neuro-Oncology. On the corporate front, the company transferred its shares to the ordinary list of the Spotlight Stock Market and terminated its liquidity provider agreement with Mangold Fondkommission AB following sustained satisfactory trading activity.